Literature DB >> 19892525

QTc interval in a sample of long-term schizophrenia inpatients.

Ramón Ramos-Ríos1, Manuel Arrojo-Romero, Eduardo Paz-Silva, Fernando Carballal-Calvo, José L Bouzón-Barreiro, Jorge Seoane-Prado, Rosario Codesido-Barcala, Alicia Crespí-Armenteros, Ramón Fernández-Pérez, Javier D López-Moríñigo, Ignacio Tortajada-Bonaselt, Francisco J Diaz, Jose de Leon.   

Abstract

This naturalistic study attempted to determine the prevalence of prolonged QTc interval in a relatively large population of inpatients hospitalized with chronic schizophrenia, and to explore QTc relationship with demographic variables, metabolic parameters and prescribed treatments. All inpatients from a Spanish long-term psychiatric hospital were cross-sectionally investigated to determine the prevalence of QTc prolongation and metabolic syndrome. The sample with a DSM-IV diagnosis of schizophrenia included 171 Caucasian inpatients, all of Spanish origin. A prolonged QTc interval was defined as >450 ms in men and >470 ms in women. The relationships between QTc and other continuous variables were assessed using a linear regression model with QTc as the dependent variable. Only 10 patients (6%) had a prolonged QTc interval; one case was possibly explained by hypokalemia. Three patients (2%) had a QTc > 500 ms. Gender, old age (> or = 50 years old), current smoking, systolic blood pressure, HDL cholesterol and history of arrhythmia were found to have significant effects on QTc interval in a linear regression analysis. After controlling for significant variables, the mean QTc interval was not significantly influenced by antipsychotic dose, type of antipsychotic treatment, the use of depot antipsychotics, or the number of different antipsychotics prescribed. Our study focused on long-term schizophrenia inpatients with frequent antipsychotic polypharmacy and high antipsychotic doses, and suggested that after excluding the case with hypokalemia length of QTc was associated with history of arrhythmias and with metabolic factors, while the effects of antipsychotic compound or class were not so evident.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19892525     DOI: 10.1016/j.schres.2009.09.041

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  11 in total

1.  Safety and tolerability of antipsychotic polypharmacy.

Authors:  Juan A Gallego; Jimmi Nielsen; Marc De Hert; John M Kane; Christoph U Correll
Journal:  Expert Opin Drug Saf       Date:  2012-05-08       Impact factor: 4.250

2.  Molecular analysis of potassium ion channel genes in sudden death cases among patients administered psychotropic drug therapy: are polymorphisms in LQT genes a potential risk factor?

Authors:  Sayako Kamei; Noriko Sato; Yuta Harayama; Miyako Nunotani; Kanae Takatsu; Tetsuya Shiozaki; Tokutaro Hayashi; Hideki Asamura
Journal:  J Hum Genet       Date:  2013-11-28       Impact factor: 3.172

Review 3.  Antipsychotic Polypharmacy and Corrected QT Interval: A Systematic Review.

Authors:  Hiroyoshi Takeuchi; Takefumi Suzuki; Gary Remington; Hiroyuki Uchida
Journal:  Can J Psychiatry       Date:  2015-05       Impact factor: 4.356

4.  Prevalence and correlates of QTc prolongation in Italian psychiatric care: cross-sectional multicentre study.

Authors:  M Nosè; I Bighelli; M Castellazzi; G Martinotti; G Carrà; C Lucii; G Ostuzzi; F Sozzi; C Barbui
Journal:  Epidemiol Psychiatr Sci       Date:  2015-10-15       Impact factor: 6.892

5.  Sex difference in QTc prolongation in chronic institutionalized patients with schizophrenia on long-term treatment with typical and atypical antipsychotics.

Authors:  Fu De Yang; Xiang Qun Wang; Xiu Ping Liu; Ke Xin Zhao; Wei Hong Fu; Xue Ru Hao; Xing Li Zhang; Guo Shu Huang; Sheng Cai Qu; Jing Shen Bai; Xu Feng Huang; Thomas R Kosten; Xiang Yang Zhang
Journal:  Psychopharmacology (Berl)       Date:  2011-02-09       Impact factor: 4.530

6.  A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls.

Authors:  Davy Vancampfort; Martien Wampers; Alex J Mitchell; Christoph U Correll; Amber De Herdt; Michel Probst; Marc De Hert
Journal:  World Psychiatry       Date:  2013-10       Impact factor: 49.548

7.  Two Sudden and Unexpected Deaths of Patients with Schizophrenia Associated with Intramuscular Injections of Antipsychotics and Practice Guidelines to Limit the Use of High Doses of Intramuscular Antipsychotics.

Authors:  Nasratullah Wahidi; Katie M Johnson; Allen Brenzel; Jose de Leon
Journal:  Case Rep Psychiatry       Date:  2016-08-15

8.  Prevalence of ECG abnormalities and risk factors for QTc interval prolongation in hospitalized psychiatric patients.

Authors:  Nicolas Ansermot; Meredith Bochatay; Jürg Schläpfer; Mehdi Gholam; Ariane Gonthier; Philippe Conus; Chin B Eap
Journal:  Ther Adv Psychopharmacol       Date:  2019-12-12

Review 9.  Etiology of cardiovascular disease in patients with schizophrenia: current perspectives.

Authors:  Murat Emul; Tevfik Kalelioglu
Journal:  Neuropsychiatr Dis Treat       Date:  2015-10-01       Impact factor: 2.570

10.  QT is longer in drug-free patients with schizophrenia compared with age-matched healthy subjects.

Authors:  Kumiko Fujii; Yuji Ozeki; Hiroaki Okayasu; Yumiko Takano; Takahiro Shinozaki; Hiroaki Hori; Masami Orui; Minoru Horie; Hiroshi Kunugi; Kazutaka Shimoda
Journal:  PLoS One       Date:  2014-06-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.